Relypsa (RLYP) shares are up sharply in pre-market trading today as investors Veltassa data for the month of June and the three-month period ended June 30, 2016. In the month of June, 1,531 new patients began taking Veltassa with a free starter supply. 1,723 outpatient prescriptions were covered by payers and dispensed (retail TRx). 392 units were sold to hospitals and other institutions (non-retail).
The numbers are decent in my opinion. So far, Veltassa commercialization has been progressing well. Commercialization efforts will get a significant boost once the sNDA for Veltassa is approved though.